VentriPoint Diagnostics (VPT) Investor update summary

Product and commercialization foundation

• VMS provides AI-enhanced cardiac volumetric measurements comparable to MRI, works with ultrasound systems from any vendor, and is approved in the U.S., Europe and Canada; China approval is pending.

• VMS+ Version 4.0 is in commercialization; it received a 2026 Gold Edison Award, while a Version 3.0 usability study recorded 98% task completion, no critical errors and an average workflow under 15 minutes.

• Scalable training, installation and customer support processes are being built; manufacturing quality and regulatory audits were successful, with further work underway on system connectivity and workflow integration.

Commercial progress and outlook

• A subscription-based Device-as-a-Service model, virtual demonstrations and expanded hospital evaluations aim to reduce upfront purchasing friction and build recurring revenue.

• Q1 included a unit sale; Q2 brought a U.S. commitment to purchase two systems; Q3 included a European evaluation shipment and a unit manufacture and sale; a U.K. study began in Q4.

• Innovate BC committed funding for the Providence Health Care Ventures collaboration, which forecasts three system placements and is intended to anchor a hub-and-spoke care model.

• The CRM program is generating more than one qualified lead per week; backlog includes roughly half a dozen qualified leads or units needing installation and training, with inventory for another couple dozen units.

• Management said it is pushing for next-year sales well over CAD 1 million and expects activity to build from Q1 2027; it described the current quarter as potentially a record quarter.

Partnerships and market access

• The AIRES study, led by Royal Wolverhampton NHS Trust, will evaluate VMS in oncology patients receiving breast cancer chemotherapy, a use case focused on monitoring cardiac function.

• UniDoc discussions are advancing from a non-exclusive, non-binding MoU toward a more formal arrangement; the hub-and-spoke model targets remote, rural, Indigenous and underserved communities.

• The Ollie Hinkle Heart Foundation partnership targets pediatric cardiac imaging access; its first system was manufactured and scheduled for shipment, while Ella's Umbrella and Jovie's Joy contributed toward U.S. Midwest systems.

• VMS+ was submitted to China's NMPA and qualifies for Green Channel review; Lishman integrates VMS into its product under a software-and-sensor license, with potential investment tied to Chinese approval.

• Initial Ascend Cardiovascular integration is complete, with a more advanced roadmap contingent on funding; discussions are also underway with distributors in MENA, Brazil, India and Southeast Asia.